Cargando…
Development and Validation of a Tumor Mutation Burden–Related Immune Prognostic Model for Lower-Grade Glioma
Tumor mutation burden (TMB) is a useful biomarker to predict prognosis and the efficacy of immune checkpoint inhibitors (ICIs). In this study, we aimed to explore the prognostic value of TMB and the potential association between TMB and immune infiltration in lower-grade gliomas (LGGs). Somatic muta...
Autores principales: | Yin, Wen, Jiang, Xingjun, Tan, Jun, Xin, Zhaoqi, Zhou, Quanwei, Zhan, Chaohong, Fu, Xianyong, Wu, Zhaoping, Guo, Youwei, Jiang, Zhipeng, Ren, Caiping, Tang, Guihua |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7468526/ https://www.ncbi.nlm.nih.gov/pubmed/32974146 http://dx.doi.org/10.3389/fonc.2020.01409 |
Ejemplares similares
-
METTL7B is a novel prognostic biomarker of lower-grade glioma based on pan-cancer analysis
por: Jiang, Zhipeng, et al.
Publicado: (2021) -
Molecular Subtypes Based on the Stemness Index Predict Prognosis in Glioma Patients
por: Tan, Jun, et al.
Publicado: (2021) -
Development of an Immune-Related LncRNA Prognostic Signature for Glioma
por: Cao, Yudong, et al.
Publicado: (2021) -
Multi-Omics Analysis Based on Genomic Instability for Prognostic Prediction in Lower-Grade Glioma
por: Cao, Yudong, et al.
Publicado: (2022) -
A prognostic signature based on snoRNA predicts the overall survival of lower-grade glioma patients
por: Zhou, Yi, et al.
Publicado: (2023)